<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562897</url>
  </required_header>
  <id_info>
    <org_study_id>OOS-CANCER-7</org_study_id>
    <nct_id>NCT03562897</nct_id>
  </id_info>
  <brief_title>Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer</brief_title>
  <official_title>Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of
      patients, including a better tolerance to neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General Objectives -To identify the efficacy of the nutritional supplement Ocoxin-viusid to
      increase the quality of life of patients with epithelial advanced or metastatic ovarian
      cancer. Specific Objectives - Identify the influence of the research product on the
      nutritional status and quality of life of patients. - Describe the toxicity of the research
      product. - Identify the adverse reactions to the chemotherapy scheme and quantify the
      interruptions to it by acute toxicity.

      Quality of life. It will be measured as: - EORTC Questionnaire QLQ-C30 (Score of each item
      and general score). Measurement time: at the beginning and 3 weeks after the 3rd cycle of QT
      - EORTC Questionnaire QLQ-OV28 (Score of each item and general score). Measurement time: at
      the beginning and 3 weeks after the 3rd cycle of QT - Karnofsky index (Score of 0-100 points
      at intervals of 10). Measurement time: at the beginning, in each cycle of QT and 3 weeks
      after the 3rd cycle of QT
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 months</time_frame>
    <description>It will measured by: - EORTC QLQ-C30 (Points of every item and final points)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 months</time_frame>
    <description>Karnofsky index (Score of 0-100 points at intervals of 10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 months</time_frame>
    <description>EORTC QLQ-OV28 (Points of every item and final points)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutritional State</measure>
    <time_frame>4 months</time_frame>
    <description>Body mass index</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Carcinoma</condition>
  <condition>Ovarian Neoplasm</condition>
  <condition>Endocrine Gland Neoplasm</condition>
  <condition>Urogenital Neoplasms</condition>
  <condition>Ovarian Diseases</condition>
  <condition>Adnexal Diseases</condition>
  <condition>Genital Diseases, Female</condition>
  <condition>Female Urogenital Diseases</condition>
  <condition>Female Urogenital Diseases and Pregnancy Complications</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Gonadal Disorders</condition>
  <condition>Genital Neoplasm, Female</condition>
  <condition>Neoplasms, Glandular and Epithelial</condition>
  <arm_group>
    <arm_group_label>Ocoxin-Viusid®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocoxin-Viusid® before, during and after the Chemotherapy treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ocoxin-Viusid</intervention_name>
    <description>Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).</description>
    <arm_group_label>Ocoxin-Viusid®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients 18 years of age or older.

          2. Patients with diagnosis of ovarian epithelial cancer in stages III (not resectable)
             and IV.

          3. Patients with general health status according to the Karnofsky Index ≥ 70 (Annex 12).

          4. Life expectancy equal to or greater than 3 months.

          5. Patients who give their informed consent in writing to participate in the study.

          6. Normal functioning of organs and bone marrow defined by the following parameters:
             -Hemoglobin ≥ 90 g / L - Total Leukocyte count ≥ 3.0 x 109 / L Absolute Neutrophil
             Count = 1.5 x 109 / L -Platelet count ≥ 100 x 109 / L -Glycemia values ≤ 10 Umol / L
             -Values of Creatinine and total bilirubin within the normal limits of the institution.
             -Values of AST / ALT ≤2.5 times the upper limit of the normal interval established in
             the institution.

          7. Patients with a history of cardiovascular disease, with ejection fraction ≥ 55%,
             measured by echocardiogram.

        Exclusion Criteria:

          1. Patients who are receiving another research product.

          2. Patients with known hypersensitivity to QT with Carboplatin, Cisplatin and / or
             Paclitaxel.

          3. Patients in stage III tributary of surgical treatment at diagnosis.

          4. Patients with known hypersensitivity to any ingredient of the product research.

          5. Decompensated intercurrent diseases, including: active infections, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver diseases
             and psychiatric illnesses that could limit adherence to the requirements of the
             clinical trial or any other special condition that at the discretion of the physician
             put your health or life at risk during your participation in the trial.

          6. Pregnancy, breastfeeding or puerperium.

          7. Patients with brain metastases and/or leptomeningeal carcinosis.

          8. Patients' carrier of the human immunodeficiency virus (HIV).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roselin Valle Cabrera</last_name>
    <phone>+53-72164224</phone>
    <email>roselin@cencec.sld.cu</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Oncology and Radiobiology (INOR)</name>
      <address>
        <city>Havana</city>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Lopez Miguel, Dr.</last_name>
      <phone>+53-78388589</phone>
      <email>karenlopez@infomed.sld.cu</email>
    </contact>
    <investigator>
      <last_name>Karen López Miguel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaniurka Cruz Camejo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Selis Pomar, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Linchenat Lambert, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan M. Silveira Pablo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Esperón Noa, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karelia Silvera Candó, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivian Diéguez Rodríguez, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaida Lastres Sosa, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Idelmis Curbelo Heredia, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mircea Betancourt Cabeza, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan J. Lence Anta, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <reference>
    <citation>Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012 Sep;23 Suppl 10:x111-7.</citation>
    <PMID>22987944</PMID>
  </reference>
  <reference>
    <citation>Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011 May-Jun;61(3):183-203. doi: 10.3322/caac.20113. Epub 2011 Apr 26.</citation>
    <PMID>21521830</PMID>
  </reference>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.</citation>
    <PMID>25559415</PMID>
  </reference>
  <reference>
    <citation>Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):995-1005. doi: 10.1200/JCO.2006.07.9970. Epub 2008 Jan 14. Review.</citation>
    <PMID>18195328</PMID>
  </reference>
  <reference>
    <citation>Fuchs-Tarlovsky V, Alvarez-Altamirano K, Turquie-Sacal D, Alvarez-Flores C, Hernandez-Steller H. Nutritional status and body composition are already affected before oncology treatment in ovarian cancer. Asia Pac J Clin Nutr. 2013;22(3):426-30. doi: 10.6133/apjcn.2013.22.3.12.</citation>
    <PMID>23945413</PMID>
  </reference>
  <reference>
    <citation>Gupta D, Lis CG, Vashi PG, Lammersfeld CA. Impact of improved nutritional status on survival in ovarian cancer. Support Care Cancer. 2010 Mar;18(3):373-81. doi: 10.1007/s00520-009-0670-y. Epub 2009 May 31.</citation>
    <PMID>19484479</PMID>
  </reference>
  <reference>
    <citation>Kathiresan AS, Brookfield KF, Schuman SI, Lucci JA 3rd. Malnutrition as a predictor of poor postoperative outcomes in gynecologic cancer patients. Arch Gynecol Obstet. 2011 Aug;284(2):445-51. doi: 10.1007/s00404-010-1659-y. Epub 2010 Aug 29.</citation>
    <PMID>20803205</PMID>
  </reference>
  <reference>
    <citation>Madhok BM, Yeluri S, Haigh K, Burton A, Broadhead T, Jayne DG. Parenteral nutrition for patients with advanced ovarian malignancy. J Hum Nutr Diet. 2011 Apr;24(2):187-91. doi: 10.1111/j.1365-277X.2010.01127.x.</citation>
    <PMID>21843153</PMID>
  </reference>
  <reference>
    <citation>Billson HA, Holland C, Curwell J, Davey VL, Kinsey L, Lawton LJ, Whitworth AJ, Burden S. Perioperative nutrition interventions for women with ovarian cancer. Cochrane Database Syst Rev. 2013 Sep 11;(9):CD009884. doi: 10.1002/14651858.CD009884.pub2. Review.</citation>
    <PMID>24027084</PMID>
  </reference>
  <reference>
    <citation>Lohsiriwat V. The influence of preoperative nutritional status on the outcomes of an enhanced recovery after surgery (ERAS) programme for colorectal cancer surgery. Tech Coloproctol. 2014 Nov;18(11):1075-80. doi: 10.1007/s10151-014-1210-4. Epub 2014 Sep 13.</citation>
    <PMID>25216721</PMID>
  </reference>
  <reference>
    <citation>Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998 Mar;34(4):503-9.</citation>
    <PMID>9713300</PMID>
  </reference>
  <reference>
    <citation>Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev. 1999 Oct;4(5):304-29. Review.</citation>
    <PMID>10559547</PMID>
  </reference>
  <reference>
    <citation>Lamson DW, Brignall MS. Natural agents in the prevention of cancer, part two: preclinical data and chemoprevention for common cancers. Altern Med Rev. 2001 Apr;6(2):167-87. Review.</citation>
    <PMID>11302780</PMID>
  </reference>
  <reference>
    <citation>Al-Mahtab M, Akbar SM, Khan MS, Rahman S. Increased survival of patients with end-stage hepatocellular carcinoma due to intake of ONCOXIN®, a dietary supplement. Indian J Cancer. 2015 Jul-Sep;52(3):443-6. doi: 10.4103/0019-509X.176699.</citation>
    <PMID>26905163</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dietary supplements</keyword>
  <keyword>Ocoxin-Viusid</keyword>
  <keyword>Nutritional supplement</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Urogenital Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Ovarian Diseases</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Genital Diseases, Female</mesh_term>
    <mesh_term>Adnexal Diseases</mesh_term>
    <mesh_term>Gonadal Disorders</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

